CPDR News Archive

News banner

CPDR News Archive

June 23, 2016

Dr. Charles P. Xavier Takes the Robert A. Phillips Award and a Navy-wide Academic Research Competition Award

by Paula Amann
Published in the June 2016 issue of Military Medical Research News, a monthly newsletter of the Department of Research Programs, Walter Reed National Military Medical Center.

Fine-tuning facial transplants, predicting bone fractures, shrinking prostate cancers with new drugs and cutting the costs of surgical training with the right technology: These were among the problems probed by competition winners for 2016 Research and Innovation Month at Walter Reed National Military Medical Center (WRNMMC).

The events, during Poster Display Week on May 11 and the Research Symposia on May 18-19, drew abstracts for 178 projects. After winnowing by pre-selection judges, 22 finalists emerged in three categories: case reports, evidence-based practice and quality improvement (a crucial non-research area).

Another 24 finalists, split evenly between laboratory and clinical research, vied for the Robert A. Phillips (RAP) and Bailey K. Ashford (BKA) Awards. The two BKA winners were LCDR Gabriel Santiago, MC (laboratory medicine), and LT Scott Wagner, MC (clinical medicine).

RAP winners included LT Daniel Griffin, MC (resident laboratory category); CPT Sarah Placek, MC (resident clinical); Charles P. Xavier, Ph.D. (staff laboratory); and Benjamin Sheffield (staff clinical).

Read Full Article

May 28, 2016

 

Highlights at the 2016 AUA Annual Meeting in San Diego, Ca

The Center for Prostate Disease Research (CPDR) multi-disciplinary team - together with collaborators - presented 13 abstracts in moderated poster or podium presentations at the American Urological Association (AUA) Annual Meeting, May 6-10, 2016, San Diego, CA. The team was co-led by COL David McLeod, (Ret), MD, CPDR Director and Professor of the Department of Surgery, Uniformed Services University of the Health Sciences (USU) and the Walter Reed National Military Medical Center (WRNMMC); Dr. Shiv Srivastava, CPDR Co-Director and Professor in the Department of Surgery at USU and WRNMMC; COL Inger Rosner, MD, Associate Director, CPDR and Associate Professor, Department of Surgery, USU and the WRNNMC; Dr. Jennifer Cullen, Director of Epidemiology Research Program, CPDR and Research Assistant Professor, Department of Surgery, USU and WRNMMC and Dr. Albert Dobi, Associate Director, CPDR and Research Assistant Professor, Department of Surgery , USU and WRNMMC.

Read Full Article

May 13, 2016

 

CPDR Student Participant Wins The AACR Gary J. Miller Undergraduate Prize for Cancer and Cancer Related Biomedical Research

A third place prize in the AACR Undergraduate Student Caucus and Poster Competition was awarded to Ms. Shahnoza Dusmatova, a CPDR participant in the DoD "Research and Education Program for Historically Black Colleges and Universities and Minority-Serving Institutions (HBCU/MI)". Her poster was entitled : “Novel Appearance and Clinico-Pathologic Dynamics of TMPRSS2:ERG hybrid Prostate Cancer”. Her mentors include Dr. Kumar (UDC), Dr. Isabell Sesterhenn (JPC), Dr. Jennifer Cullen (CPDR), Dr. Shiv Srivastava (CPDR), and Dr. Taduru Sreenath (CPDR).

Shahnoza Dusmatova (left) with Dr. Rina Das, Ph.D. (National Institute on Minority Health and Health Disparities, Division of Scientific Programs, Office of Research Training and Capacity Building).

 

May 2, 2016

CPDR Presentations and Highlights at the 2016 AACR Annual Meeting in New Orleans, La.

The Center for Prostate Disease Team has presented their new findings in prostate cancer research at the American Association for Cancer Research Annual Meeting 2016 in New Orleans, Louisiana, USA.

The Team led by Dr. David G. McLeod, Director and Dr. Shiv Srivastava, Co-Director presented the ground breaking discovery of the first recurrent cancer genomic defect of prostate cancers of African American men revealed by whole genome sequencing. The title of the poster presentation was “LSAMP gene deletion is associated with rapid disease progression in prostate cancer of African American men”.

Analyzing the thus far largest and most comprehensive whole mounted prostate cancer specimens for ERG expression, obesity, African American and Caucasian American ethnicity for associations with disease progression the team co-led by Dr. Isabell Sesterhenn and Dr. Jennifer Cullen reported new insights in their poster presentation “ERG-negative index tumor status combined with obesity predict prostate cancer progression in Caucasian American prostate cancer patients”.

Along these lines presentations from the CPDR Team reported initial insights into the development of an ERG-selective inhibitor, ERGi-USU in their poster presentation “ERG oncogene-specific inhibitors for prostate cancer”. Further report from CPDR assessed potential autoantibodies with the long-term goal of prostate cancer diagnosis in the poster presentation “Immunobiomarkers: novel autoantibody panel comprising oncogenic ERG, C-MYC, AMACR and HERV-K Gag for the detection of prostate cancer”.

New insights into the mechanism of ERG action examining in vivo transgenic models of ERG highlighted the role of endoplasmic reticulum stress in the poster presentation of “ERG oncogenic activation leads to the endoplasmic reticulum stress and cell survival mechanisms”.

Poster Presentations:

    • Distinguing features of ERG oncoprotein expression among matched cohorts of African-American and Caucasian-American prostate cancer patients
      Taduru L. Sreenath, Albert Dobi, Shiela S. Macalindong, Natallia Mikhalkevich, Shashwat Sharad, Parameet Kumar, Denise Young, Rishita Gupta, Shilpa Katta, Ahmed Mohamed, Shyh-Han Tan, Gyorgy Petrovics, Charles J. Bieberich, Isabell A. Sesterhenn, Peter Nelson, David G. McLeod, Valeri Vasioukhin, Shiv Srivastava
    • ERGi-USU, A Selective Inhibitor Of ERG Oncogene Positive Cancer Cells
      Ahmed A. Mohamed, Gauthaman Sukumar, Charles P Xavier, Shilpa Katta, Lakshmi Ravindranath, Muhammad Jamal, Taduru Sreenath, David G. McLeod, Gyorgy Petrovics, Meera Srivastava, Albert Dobi, Clifton L. Dalgard and Shiv Srivastava
    • Interaction between ERG Status, Obesity & Race in Predicting Prostate Cancer Progression in a Military Cohort
      Jennifer Cullen, Denise Young, Yongmei Chen, Michael Degon, James Farrell, Jason Sedarsky, Wagner Baptist, Philip Rosen, Vladimir Tolstikov, Michael Kiebesh; Jacob Kagan, Sudhir Srivastava, Huai-Ching Kuo, Joel T. Moncur, Inger L. Rosner, Niven Narain, Viatcheslav Akmaev, Gyorgy Petrovics, Albert Dobi, David G. McLeod, Shiv Srivastava, Isabell A. Sesterhenn
    • LSAMP gene deletion is associated with rapid disease progression in prostate cancer of African American men
      Albert Dobi, Gyorgy Petrovics, Hua Li, Shyh-Han Tan, Tanja Stümpel, Denise Young, Shilpa Katta, Qiyuan Li, Kai Ying, Bernward Klocke, Lakshmi Ravindranath, Indu Kohaar, Yongmei Chen, Dezső Ribli, Korbinian Grote, Hau Zou, Joseph Cheng, Clifton L. Dalgard, Shimin Zhang, István Csabai, Jacob Kagan, David Takeda, Massimo Loda, Sudhir Srivastava, Matthias Scherf, Martin Seifert, Timo Gaiser, David G. McLeod, Zoltan Szallasi, Reinhard Ebner, Thomas Werner, Isabell A. Sesterhenn, Matthew Freedman, Shiv Srivastava
    • Autoantibodies Against ERG, AMACR, C-MYC and HERV-K Gag in the Sera Of Prostate Cancer Patients: Potential Use in Diagnosis/Prognosis
      Anshu Rastogi, Shyh-Han Tan, Amina Ali, Yongmei Chen, Jennifer Cullen, Sreedatta Banerjee, Ahmed A. Mohamed, Lakshmi Ravindranth, Denise Young, Isabell A. Sesterhenn, Jacob Kagan, Sudhir Srivastava, David G. McLeod, Gyorgy Petrovics, Albert Dobi, Shiv Srivastava, Alagarsamy Srinivasan
    • Novel Appearance and Clinico-Pathologic Dynamics of TMPRSS2:ERG Hybrid Prostate Cancer
      Shahnoza Dusmatova, William Gesztes, Lauren Hurwitz, Huai-Ching Kuo, Denise Young, Inger Rosner, Jennifer Cullen, Deepak Kumar, Shiv Srivastava , Isabell Sesterhenn 

 

February 2, 2016

CPDR Urology Residents Take Top Awards at 2016 James C. Kimbrough Urological Seminar

Urology Residents conducting research at The Center for Prostate Disease Research (CPDR), Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center presented their research at the Residents Competition category of the James C. Kimbrough Urological Seminar, San Diego, 2016.

LT Travis Allemang, MD, a fifth-year resident at the Naval Medical Center Portsmouth and Eastern Virginia Medical School, won 1st place for his presentation titled "Prostate Cancer Gene Expression Signatures Associated with Seminal Vesicle Invasion and Biochemical Recurrence after Radical Prostatectomy”. CPT Jason Sedarsky, MD, a fifth-year resident at Urology Service Walter Reed National Military Medical Center won 3rd place for his presentation “Racial Differences of ERG Frequencies in Prostate Cancer. CPT Daniel Kim, MD, a fourth-year Urology Resident presented his research findings on “Patterns in Treatment Decision-Making and Longitudinal Regret for Low Risk Prostate Cancer Patients Managed on Active Surveillance”. Congratulations to all!

Since 1993, CPDR, Department of Surgery, USUHS, and the Urology Service at WRNMMC have been training next-generation urologists and future leaders in the field through the state-of-the-art Urology Resident Training and Education Program. Urology Residents trained at CPDR have been following the great traditions of excellence with their award-winning research work focused on prostate cancer translation research, within the Basic Science Research Program, led by Dr. Shiv Srivastava, Co-Director, CPDR, and Dr. Isabell Sesterhenn, Chief, Genitourinary Pathology at the Joint Pathology Center.

Dr. Albert Dobi, PhD, Associate Director BSRP, CPDR said, “The recognition of these exceptionally innovative research achievements highlight the success of the CPDR multi-disciplinary program and demonstrates the commitment of CPDR, Department of Surgery, USUHS and the WRNMMC to serve DoD patients with prostate cancer by nurturing talents from all arms of the U.S. Armed Forces.”

 

January 11, 2016

A Novel Gene Alteration Associates with Aggressive Prostate Cancer in African American Men

The USU, Walter Reed-Bethesda and JPC collaborative team, through comprehensive evaluations of matched cohorts of African American and Caucasian American prostate cancers, previously established a higher frequency of ERG alterations in Caucasians (50-70%) and its significantly lower frequency in African Americans (20-25%). These intriguing observations actually provided the rational for the current study focusing on whole genome evaluations of prostate cancers from these two patient populations.

 

Read Full Article

March 30, 2015

CytoTest and Uniformed Services University’s Center for Prostate Disease Research enter into CRADA to advance cancer diagnosis and prognosis

ROCKVILLE, Maryland, March 30, 2015 – CytoTest Inc., the Uniformed Services University of the Health Sciences (USU), and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) announced today that they have signed a Cooperative Research and Development Agreement (CRADA).

Under the terms of the CRADA, CytoTest will collaborate with the Center for Prostate Disease Research (CPDR) on the development of next-generation approaches to prostate cancer diagnosis and prognosis. CPDR is a Department of Defense Prostate Center of Excellence program of USU’s Department of Surgery, administered by HJF. Both USU and HJF are located in Bethesda, Maryland.

CPDR has discovered a number of genetic and biochemical prostate cancer markers with the potential to be used as early diagnostic or prognostic indicators. As part of the initial CRADA efforts with CPDR, CytoTest will provide reagents, instrumentation, manufacturing, scale-up, biomarker screening services and assay construction capabilities to advance the development of these markers for use in clinical diagnostic testing.

The collaboration combines CPDR’s discovery and translational research abilities and unique clinical resources with CytoTest’s genomic medicine expertise and diagnostic assay development infrastructure. The studies will be conducted under the direction of Shiv Srivastava, Ph.D., CPDRs Co-director and Scientific Director, and Professor in USU’s Department of Surgery, working with a research and development team led by Reinhard Ebner, Ph.D., Chief Scientific Officer at CytoTest.

“We are enthusiastic and honored to assist an exceptional institution such as CPDR in their cutting-edge basic and clinical research efforts,” said Joseph Cheng, President and CEO of CytoTest. “The collaboration is especially rewarding since investigators at CPDR and in our company have been engaged in fruitful working relationships for some time. Leveraging CPDR’s latest discoveries with CytoTest’s expertise in cytogenetic analysis and our resources for validating and optimizing genomics-based diagnostic assays, this CRADA is an exciting milestone for CytoTest.”

“During our investigations of regulation, expression and functions of prostate cancer-associated genes, we have uncovered a highly promising series of candidates for early detection as well as biomarkers with prognostic potential,” said Albert Dobi, Ph.D., Associate Director at CPDR. “We look forward to seeing some of these discoveries advance closer to the clinic.”

“From the beginning, our basic science and translational research program has brought together urologists, cancer biologists, pathologists, epidemiologists, and bioinformatics and clinical research experts striving to combat prostate cancer,” said Dr. Srivastava. “Innovative project partnerships are an integral component of our efforts toward developing and evaluating novel technologies for improving diagnosis, prognosis and personalized medicine of prostate cancer.”

Prostate cancer is the most commonly diagnosed non-cutaneous cancer in men and the second most common cause of male death from cancer. In 2015, approximately 220,800 men in the U.S. will be diagnosed with prostate cancer and an estimated 27,540 men will die from the disease.

Prostate cancer is also characterized by significant health disparities, with striking differences in incidence and mortality among ethnic, social and geographic patient groups, precipitating intensive investigations in search of sub-population specific biomarkers and therapies.

Read the Article at Cytotest site

 

March 20, 2015

Collaborative Summer Training Program for HBCU Undergraduates in Washington, DC

Since its introduction in 2004, the goal of the PCRP’s Collaborative Undergraduate HBCU Student Summer Training Program Award has been to provide educational and training opportunities for HBCU undergraduate students at a critical decision-making point in their education, with the expectation that these trainees will pursue careers in prostate cancer research and thus increase the cadre of the next generation of researchers who will, in turn, make new discoveries and develop innovative treatments for prostate cancer.

Dr. Shiv Srivastava received an FY07 PCRP Collaborative Undergraduate HBCU Student Summer Training Program award to provide foundational cancer research opportunities for undergraduates at the University of the District of Columbia (UDC) through the Uniformed Services University of the Health Sciences (USUHS) – Center for Prostate Disease Research (CPDR). In this collaborative effort, Dr. Deepak Kumar served as the Partnering Principal Investigator at UDC. This program allowed UDC students with limited to no exposure in biomedical research to gain experience in state-of-the-art prostate cancer translational research.

Through the dynamic 10-week summer program at CPDR, students strengthened what they had already learned – in college science courses – by focusing on prostate cancer. They interacted with leading prostate cancer researchers, learned how to work effectively in teams, and developed the skills needed to present their research findings through regular seminars. Students also learned about the current trends in cancer research, including the biologic basis of prostate cancer health disparities.

This program has provided a gateway for students to pursue careers in biomedical and prostate cancer research. Ten (10) of the 16 students trained in the program are pursuing graduate/medical/professional schools, and they attribute their success to the UDC-CPDR program. Students have presented their research at various national conferences, including the PCRP’s IMPaCT meeting; they have also gone on to win several awards for their presentations. In summary, this has helped expose UDC students to biomedical and prostate cancer research, guiding them into professional/graduate/medical schools, and providing them with the opportunity to join the biomedical workforce and develop into the next generation of prostate cancer researchers. Based on the program’s success, Drs. Srivastava and Kumar received another HBCU Student Summer Training Program award from the PCRP in FY13. This will ensure that current and future students at UDC will have the opportunity to participate in this valuable training program for several summers to come.

Read the Article in the Congressionally Directed Medical Research Programs (CDMRP) Prostate Cancer Reseach Program Brochure (pg 13)

September 29, 2014

Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients

REDWOOD CITY, CA – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence).

Read Full Article

 

August 21, 2014

ERG Monoclonal Antibody [9FY] Patent Issued To The Uniformed Services University Of The Health Sciences Center For Prostate Disease Research & Biocare Medical

Concord, CA – The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has been awarded a patent in the United States (Patent No: US 8,765,916 B2) and Europe for ERG monoclonal antibodies. The patent is pending in Australia, Canada and Japan. ERG mouse antibody 9FY is a rigorously characterized antibody for its specificity of the ERG protein detection among the closely related members of the ETS transcription factor family in biological specimens.

Read Full Article

 

August 6, 2014

Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints

Redwood City, CA – PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a ...

Read Full Article

August 31, 2012 

Ethnic Disparity Paper Published in Urology

The team at CPDR is proud to announce its seventh publication of 2012. "Differences in Frequency of ERG Oncoprotein Expression between Index Tumors of Caucasian and African American Patients with Prostate Cancer" was published in Urology (The Gold Journal) online on August 29, 2012. The article is in press and will also appear in an upcoming print journal. The authors found that ERG typing of prostate cancer established a major difference between the index tumors of Caucasian and African American patients. The results of this study underscore that typing of prostate cancer for ERG could enhance the understanding of the biologic differences between Caucasian and African American men.

The online abstract can be found here: Full Article

 

August 10, 2012 

Five Students Complete CPDR Summer Student

On August 10, 2012, five students from the Center for Prostate Disease Research (CPDR) Department of Surgery, Uniformed Services University of the Health Sciences (USUHS) Summer Student Professional Development Program completed their research projects and presented their data and results to CPDR staff and senior USUHS leadership. Their research efforts will contribute to a multitude of ongoing projects within CPDR and their results and data were well received by all in attendance.

Read More

 

June 20, 2012 

CPDR Announces Partnership with AUAF for 2-Year Fellowship Program

The Center for Prostate Disease Research (CPDR), along with the American Urological Association Foundation (AUAF), is announcing a partnership to provide support for a two-year fellowship through AUAF's Research Scholars Program. The awarded fellow will receive $80,000 during the course of two years to complete a research project dealing with genetics alterations associated with the following:

  • Discovery and validation of prognostic markers of aggressive prostate cancer;
  • Developing prostate cancer-specific diagnostic markers that will improve the specificity of serum PSA tests;
  • Developing better understanding of molecular bases of cancer susceptibility in high risk cancer groups (e.g., African Americans);
  • Developing new therapeutic strategies focusing on causal gene alterations in prostate cancer

 

Read More

 

June 8, 2012 

CPDR Presentations and Highlights at the 2012 AUA Annual Meeting in Atlanta, GA; May 19-23

In addition to Dr. Rosen's and Dr. Allemang's winning poster presentations, the CPDR multi-disciplinary team presented 9 other notable, moderated poster presentations at the 2012 AUA Annual Meeting. This showing – 11 presentations total – from the CPDR team is one of the largest in recent history, and the directors and staff are extremely proud of the hard work and effort that the doctors and researchers have put forth. The research was led by COL David McLeod, (Ret), MD, CPDR Director and Professor at Uniformed Services University (USU) and by Shiv Srivastava, PhD, Co-Director and Professor at USU.

Read More

 

June 1, 2012 

CPT Philip Rosen, MD, and LT Travis Allemang, MD, both won the distinguished "2012 Best of Poster" award at the 2012 AUA Annual Meeting in Atlanta, GA.

On Sunday, May 20, 2012, Dr. Rosen presented his poster titled "Distinguishing Features of ERG Oncoprotein Expression Among Matched Cohorts of African-American and Caucasian-American Prostate Cancer Patients" at the 2012 AUA Annual Meeting. The next day, on Monday, May 21, 2012, Dr. Allemang presented his poster titled "Age-Associated Gene-Expression Signatures in Non-Familial Prostate Cancer."

Read More

February 14, 2011 

CPDR's ERG Antibody Leads to Successful Opportunities

The Center for Prostate Disease Research (CPDR) and the Uniformed Services University of the Health Sciences (USUHS) - with the Henry M. Jackson Foundation (HJF) for the Advancement in Military Medicine - are excited to announce a licensing agreement with Biocare Medical for the exclusive worldwide sales and distribution of the anti-ERG monoclonal antibody (ERG-MAb).

Read More

August 31, 2010 

2010 Internship Program Immerses Minority Students in Prostate Cancer Research

Five interns were selected for the 2010 program based on academic achievements at UDC in prostate cancer research. CPDR provided a structured framework for the program, offering a rich multi-disciplinary prostate cancer translational research environment that is credited for landmark discoveries. The students completed their program by presenting their training and research accomplishments at USU to leaders from the participating organizations. Dr. Taduru Sreenath, CPDR assistant director, served as the primary coordinator for the program...

 

June 29, 2010 

Scientists develop highly specific ERG monoclonal antibody for detecting common oncogenic alterations in prostate cancer.

Bethesda, Maryland--Researchers at the Uniformed Services University of the Health Sciences (USU) Center for Prostate Disease Research (CPDR), in collaboration with investigators at the Armed Forces Institute of Pathology and Walter Reed Army Medical Center have developed a highly specific assay for the detection of ERG oncoprotein that is regulated by prevalent gene fusions present in over half of all prostate cancers. These findings are reported in the advanced online publication of Prostate Cancer and Prostatic Diseases (Nature Publishing Group, June 29), "ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification."

PCAN Journal Article

USU News Release

 

June 11, 2010 

AUA 2010 Highlights

CPDR presentations and highlights at the American Urologic Association Annual Meeting San Francisco, May 30-June 3, 2010

The multi-disciplinary team of Center for Prostate Disease Research led by COL (ret) David McLeod, MD, CPDR Director and Professor at Uniformed Services University and Dr. Shiv Srivastava, PhD, Co-Director and Professor at Uniformed Services University presented five abstracts in moderated poster sections of the American Urologic Association Annual Meeting ...

Read More

 

June 10, 2010 

AACR 2010 Highlights

AACR 101st Annual Meeting Presentations from CPDR Washington DC, April 17 – 21, 2010

More than 18,000 participants from countries gathered to discuss an estimated 5,500 abstracts and to hear several hundreds of symposium presentations on significant discoveries in basic, clinical, and translational cancer research at the 101th Annual Meeting of the American Association of Cancer Research, in Washington DC. ...

Read More

November 9, 2009 

Summer Internship Program Immerses Minority Students in Prostate Cancer Research

The Uniformed Services University of the Health Sciences (USU) Center for Prostate Disease Research (CPDR) played host recently to seven students from the University of the District of Columbia for a rigorous twelve-week training internship focused on prostate cancer research. The internship was established jointly by the CPDR, which is part of USU's Department of Surgery, and the University of the District of Columbia (UDC) in 2008 ...

Full Article

 

September 1, 2009 

September is Prostate Cancer Awareness Month

As a part of this awareness effort, CPDR sponsors a Prostate Cancer Screening Day to screen military health care beneficiaries for prostate cancer.

Date: Saturday 26 September
Time: 0700-1100
Location: Walter Reed Army Medical Center, 5th Floor, CPDR Ward 56

Help us spread the word to your friends and colleagues (who are military beneficiaries) so they can be checked for prostate cancer. Early detection is the key! 

Please download and forward the flyer linked below (pdf format) to your friends and colleagues who are military health care beneficiaries -- or post it on bulletin boards at work if retired/active duty military employees. Help spread the word by doing what you can to encourage or persuade your male buddies to get smart about their PSA readings. You know how important this is--- more than anybody! A nudge from a buddy may be all that is needed! 

Prostate Screening Flyer

 

August 21, 2009 

Prostate Cancer on CNN Larry King Live!

Colin Powell, tennis champ John McEnroe and L.A. Dodger’s manager Joe Torre come together to save lives! They speak out on one of the deadliest cancers for men! Powell, McEnroe and Torre on surviving and preventing prostate cancer!

See Video Footage - 8/21/2009 Read Blog article

 

February 2, 2009 

CPDR Takes Five Awards

56th Annual James C. Kimbrough Urological Seminar

The 56th James C. Kimbrough Urological Seminar brought great recognitions to CPDR. This year the seminar was held in Washington DC.

COL (Ret.) David G.McLeod was honored with the H. G. Stevenson award. In 1992 the Society of Government Service Urologists established this award, which is presented annually for outstanding support and dedicated service to the Society. The recipient of this award can be a Corporate Member, physician, or other individual as determined by the Board of Directors.

Read the full article

November 4, 2005 

Dr Bungo Furusato Wins Outstanding Poster Award

7th Society for Urologic Oncology Annual Meeting December 1-2, 2005, Natcher Conference Center, NIH, Bethesda, Maryland

CPDR is pleased to announce that Dr Bungo Furusato, Staff Scientist, CPDR/AFIP wins the outstanding poster award at the 7th Society for Urologic Oncology Annual meeting December 1-2, 2005, Natcher Conference Center NIH Bethesda Maryland. For his poster presentation. The research was carried out under the direction of Dr Srivastava CPDR and Dr Sesterhenn, AFIP.

The title and abstract of his poster presented at the meeting

GENE EXPRESSION SIGNATURES IN BENIGN AND MALIGNANT EPITHELIAL CELLS FROM FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPE) TISSUES OF PROSTATE CANCER PATIENTS

Read More

 

December 6, 2004 

2004 Principal Investigators' Meeting

On December 2, 2004, CPDR hosted the annual Principal Investigators' Meeting at the East Jefferson site. CPDR Principal Investigators who attended the full day conference included Dr. John Ward of Naval Medical Center, Portsmouth, Dr. Trent Sterenchock from Eisenhower Army Medical Center, Ft. Gordon, Georgia, Dr. Christopher Amling from Naval Medical Center, San Diego, Dr. Keith O'Reilly from Madigan Army Medical Center, Dr. David McLeod from Walter Reed Army Medical Center and Dr. Christopher Porter from Virginia Mason Medical Center in Seattle. Dr. John Ward is an Associate Investigator who represented Dr. Leo Kusuda, Principal Investigator of Naval Medical Center Portsmouth. Other attendees included Dr. Shiv Srivastava, Dr. Rob Bienvenue, Ms. Pamela Harding, Ms. Marianne Spevak, Mr. Norbert Stingle, Ms. Stephanie Shaar, Mr. Jack Chang, Dr. Yongmei Chen, Ms. Michelle Zhao and Dr. Jennifer Cullen.

 

 

November 2, 2004 

Johng Rhim, M.D., Wins Funding for Human Cell Model Research

Johng S. Rhim, M.D., Associate Director of CPDR and Director of the CPDR Prostate Cell Center, recently received notice from the Department of Defense Prostate Cancer Research Program (PCRP) that his project, "Development of a Human Cell Model for the Study of Familial Prostate Cancer," has been recommended for funding.

In cases of familial prostate cancer, the patient has one or more family members who have also been diagnosed with or show symptoms of the disease. Familial prostate cancer constitutes 9 percent of all prostate cancer cases. Dr. Rhim's project takes tumor specimens from such patients and generates in vitro cell lines, which are living, permanently propagating cells maintained and characterized in the laboratory. Ordinarily, primary tumor cells are able to reproduce through several cycles and then senesce, or die. The special value of Dr. Rhim's work ...

 

 

November 1, 2004 

CPDR Database is featured in September issue of Oncology

Dr. Judd W. Moul, former CPDR Director and currently Professor and Chief, Division of Urologic Surgery, Duke University Medical Center, recently commented on an article in the September 2004 issue of Oncology (Moul, JW. The Cooperberg/Park/ Carroll Article Reviewed. Oncology. 2004 Sept. 18(2) 1248-1256). 

The article "Prostate Cancer 2004: Insights from National Disease Registries" relates recent prostate cancer research from collaborations between various national prostate disease database efforts including CPDR, Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) and Harvard University. 

In his review of the article, Dr. Moul discusses the usefulness of prostate-specific antigen (PSA) doubling time (the time it takes for the PSA ...

 

 

October 14, 2004 

Dr. Jennifer Cullen is the newest addition to the staff at the East Jefferson site

Hired on October 4, 2004, she is already immersed in her role as Epidemiologist in our program and is working closely with the CPDR patient database, the Clinical Research Center at Walter Reed and the Institutional Review Board. 

She hails from Havre de Grace, a small town near Baltimore, Maryland. While still young, she moved with her family to California due to her father's career change to the UCLA Cancer Center. In fact, her father was a major influence on her decision to specialize in the health sciences. He was Deputy Director of the National Cancer Institute for eight years, specializing in cancer prevention and control and even a close friend of Dr. C. Everett Koop, the former Surgeon General of the United States....

 

 

October 1, 2004 

AFUD Honors Col David McLeod

On September 30, 2004, COL David McLeod was presented the Outstanding Service Award by the American Foundation of Urologic Disease (AFUD) at a gala evening event in Northwest Washington D.C. The reception, held at a historic mansion in the heart of the city, was attended by a wide variety of military and civilian guests gathered to honor McLeod, who is chief of urologic oncology and head of the urology residency program at Walter Reed Army Medical Center, for his contributions to the medical field. He is also interim director for the DoD Center for Prostate Disease Research (CPDR), which he co-founded in 1992, at the Uniformed Services University of the Health Sciences (USUHS). After five years as president of AFUD where he served with "vision and distinction" McLeod stepped down this year to devote more time to his patients, who admire him, wait in line for hours to see him and trust his care and treatment which he gears specifically to their age, health and disease stage.

 

December 9, 2004 

CPDR Researchers Awarded NIH R01 Funding for Cell Type-Specific Gene Expression Signature Research

The Center for Prostate Disease Research (CPDR) recently received a four-year R01 grant from the National Institutes of Health (NIH) to support a research project focusing on gene expression signatures in benign and malignant epithelial and stromal cells of prostate cancer patients with aggressive and non-aggressive disease. Dr. Syed Shaheduzzamen is a co-investigator on this project.

The funded project builds upon the pioneering work CPDR has long been doing to discover and learn the translational utility of genes commonly altered in human prostate cancer (CaP). The CPDR laboratory...

Read More

 

December 6, 2004 

2004 Principal Investigators' Meeting

On December 2, 2004, CPDR hosted the annual Principal Investigators' Meeting at the East Jefferson site. CPDR Principal Investigators who attended the full day conference included Dr. John Ward of Naval Medical Center, Portsmouth, Dr. Trent Sterenchock from Eisenhower Army Medical Center, Ft. Gordon, Georgia, Dr. Christopher Amling from Naval Medical Center, San Diego, Dr. Keith O'Reilly from Madigan Army Medical Center, Dr. David McLeod from Walter Reed Army Medical Center and Dr. Christopher Porter from Virginia Mason Medical Center in Seattle. Dr. John Ward is an Associate Investigator who represented Dr. Leo Kusuda, Principal Investigator of Naval Medical Center Portsmouth. Other attendees included Dr. Shiv Srivastava, Dr. Rob Bienvenue, Ms. Pamela Harding, Ms. Marianne Spevak, Mr. Norbert Stingle, Ms. Stephanie Shaar, Mr. Jack Chang, Dr. Yongmei Chen, Ms. Michelle Zhao and Dr. Jennifer Cullen.

Read More

 

November 2, 2004 

Johng Rhim, M.D., Wins Funding for Human Cell Model Research

Johng S. Rhim, M.D., Associate Director of CPDR and Director of the CPDR Prostate Cell Center, recently received notice from the Department of Defense Prostate Cancer Research Program (PCRP) that his project, "Development of a Human Cell Model for the Study of Familial Prostate Cancer," has been recommended for funding.

In cases of familial prostate cancer, the patient has one or more family members who have also been diagnosed with or show symptoms of the disease. Familial prostate cancer constitutes 9 percent of all prostate cancer cases. Dr. Rhim's project takes tumor specimens from such patients and generates in vitro cell lines, which are living, permanently propagating cells maintained and characterized in the laboratory. Ordinarily, primary tumor cells are able to reproduce through several cycles and then senesce, or die. The special value of Dr. Rhim's work ...

Read More

 

November 1, 2004 

CPDR Database is featured in September issue of Oncology

Dr. Judd W. Moul, former CPDR Director and currently Professor and Chief, Division of Urologic Surgery, Duke University Medical Center, recently commented on an article in the September 2004 issue of Oncology (Moul, JW. The Cooperberg/Park/ Carroll Article Reviewed. Oncology. 2004 Sept. 18(2) 1248-1256). 

The article "Prostate Cancer 2004: Insights from National Disease Registries" relates recent prostate cancer research from collaborations between various national prostate disease database efforts including CPDR, Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) and Harvard University. 

In his review of the article, Dr. Moul discusses the usefulness of prostate-specific antigen (PSA) doubling time (the time it takes for the PSA ...

Read More

 

October 14, 2004 

Dr. Jennifer Cullen is the newest addition to the staff at the East Jefferson site

Hired on October 4, 2004, she is already immersed in her role as Epidemiologist in our program and is working closely with the CPDR patient database, the Clinical Research Center at Walter Reed and the Institutional Review Board. 

She hails from Havre de Grace, a small town near Baltimore, Maryland. While still young, she moved with her family to California due to her father's career change to the UCLA Cancer Center. In fact, her father was a major influence on her decision to specialize in the health sciences. He was Deputy Director of the National Cancer Institute for eight years, specializing in cancer prevention and control and even a close friend of Dr. C. Everett Koop, the former Surgeon General of the United States....

Read More

 

October 1, 2004 

AFUD Honors Col David McLeod

On September 30, 2004, COL David McLeod was presented the Outstanding Service Award by the American Foundation of Urologic Disease (AFUD) at a gala evening event in Northwest Washington D.C. The reception, held at a historic mansion in the heart of the city, was attended by a wide variety of military and civilian guests gathered to honor McLeod, who is chief of urologic oncology and head of the urology residency program at Walter Reed Army Medical Center, for his contributions to the medical field. He is also interim director for the DoD Center for Prostate Disease Research (CPDR), which he co-founded in 1992, at the Uniformed Services University of the Health Sciences (USUHS). After five years as president of AFUD where he served with "vision and distinction" McLeod stepped down this year to devote more time to his patients, who admire him, wait in line for hours to see him and trust his care and treatment which he gears specifically to their age, health and disease stage.

Read More